Assessment and predictors of antiretroviral adherence in older HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue SUPPL. 2, 2003, Pages

  Wutoh, Anthony K ^a   Elekwachi, Oluchi ^a   Clarke Tasker, Veronica ^a   Daftary, Monika ^a   Powell, Nadina J ^a   Campusano, Gregorina ^a  

^a HOWARD UNIVERSITY   (United States)

Author keywords

Adherence; Antiretroviral; Compliance; HIV AIDS

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CISPLATIN; COTRIMOXAZOLE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TETRACYCLINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; AGING; ANEMIA; ARTICLE; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; GRANULOCYTOPENIA; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; MALAISE; MALE; MYOPATHY; NAUSEA AND VOMITING; NEUROTOXICITY; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RACE DIFFERENCE; RASH; SEX DIFFERENCE; TASTE DISORDER; VIRUS INFECTION; VIRUS LOAD;

EID: 0038003158     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200306012-00007     Document Type: Article

References (73)

1. Adler WH, Nagel JE. Acquired immunodeficiency syndrome in the elderly. Drugs Aging. 1994;4:410-416.
2. Chiao EY, Ries KM, Sande MA. AIDS and the elderly. Clin Infect Dis. 1999;28:740-745.
3. Stewart RB, Cooper JW. Polypharmacy in the aged: practical solutions. Drugs Aging. 1994;4:449-461.
4. Institute of Medicine. Errors in health care, a leading cause of death and injury. In Kohn L, Corrigan J, Donaldson M, eds. Committee on Quality of Health Care in America. To err is human; building a safer health system. Washington, DC: National Academy Press; 1999:26-48.
5. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
7. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS defining events and hospitalizations in 10 French AIDS reference centres. AIDS. 1997;11(Suppl):F101-105.
8. D'Arminio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS. 1998;12:1631-1637.
9. Paterson D, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
10. Hogg R, Yip B, Chan K, et al. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women [abstract TuOrB419]. Presented at the XIII International AIDS Conference. Durban, South Africa, July 2000.
11. Pilcher CD, Miller WC, Beatty ZA, et al. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. AIDS. 1999;13:1337-1342.
12. Cinti SK. Adherence to antiretrovirals in HIV disease. AIDS Reader. 2000;10:709-717.
13. Harrigan PR, Whaley M, Montaner JG. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 1999;13(Suppl):F59-62.
14. Kaul DR, Cinti SK, Carver PL, et al. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy. 1999;19:281-298.
15. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-2505.
16. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977-1983.
17. Wutoh AK, Brown CM, Kumoji EK, et al. Antiretroviral adherence and treatment behaviors of older HIV-infected adults. J Natl Med Assoc. 2001;93:243-250.
18. Sackett DL, Snow JS. The magnitude of compliance and non-compliance. In Haynes RB, Taylor DW, Sackett DL, eds. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979:11-12.
19. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000;50:1599-1605.
20. Ostrop NJ, Hallett KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother. 2000;34:703-709.
21. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
22. Arnsten J, Demar P, Gourevitch M, et al. Adherence and viral load in HIV-infected drug users: comparison of self-report and medication event monitors (MEMS) [abstract 69]. Presented at the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January-February 2000.
23. Mannerheimer S, Friedland G, Matts J, et al. Self-reported antiretroviral adherence correlates with HIV viral load and declines over time [abstract TuORB421]. Presented at the XIII International AIDS Conference, Durban, South Africa, July 2000.
24. Maggiolo F, Migliorino M, Caprioli S, et al. Once-a-day therapy for HIV infection [abstract TuPpB1167]. Presented at the XIII International AIDS Conference, Durban, South Africa, July 2000.
25. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000:14:357-366.
26. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 2):S171-176.
27. Conference report. Adherence to new HIV therapies: a research conference. Forum for Collaborative HIV Research (FCHR), National Minority AIDS Council (NMAC). Washington, DC: NIH Office of AIDS Research, November 1997.
28. Murri R, Ammassari A, Gallicano K, et al. Relationship of self-reported adherence to HAART with protease inhibitor plasma level and viral load [abstract 593]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, September 1999.
29. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:435-442.
30. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150:841-845.
31. Cooper JK, Love DW, Raffoul PR. Intentional prescription non-adherence (noncompliance) by the elderly. J Am Geriatr Soc. 1982;30:329-333.
32. German PS, Klein LE, McPhee SJ, et al. Knowledge of and compliance with drug regimens in the elderly. J Am Geriatr Soc. 1982;30:568-571.
33. Lee JY, Kusek JW, Greene PG, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) pilot study. Am J Hypertens. 1996;9:719-725.
34. Morrell RW, Park DC, Kidder DP, et al. Adherence to antihypertensive medications across the life span. Gerontologist. 1997;37:609-619.
35. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555-567.
36. McDonald-Miszczak L, Maki SA, et al. Self-reported medication adherence and health status in late adulthood: the role of beliefs. Exp Aging Res. 2000;26:189-207.
37. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20:764-771.
38. Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc. 2000;40:475-485.
39. Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: hat doctors believe and patients actually do. Br J Clin Pharmacol. 2001;51:615-622.
40. Svensson S, Kjellgren KI, Ahlner J, et al. Reasons for adherence with antihypertensive medication. Int J Cardiol. 2000;76:157-163.
41. Coons SJ, Sheahan SL, Martin SS, et al. Predictors of medication noncompliance in a sample of older adults. Clin Ther. 1994;16:110-117.
42. Lorenc L, Branthwaite A. Are older adults less compliant with prescribed medication than younger adults? Br J Clin Psychol. 1993;32:485-492.
43. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurses AIDS Care. 1997;8:43-54.
44. Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with HIV: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261-269.
45. Bond W, Hussar D. Detection methods and strategies for improving medication compliance. Am J Public Health. 1991;1978-1988.
46. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med. 1994;154:1121-1127.
47. Lerner BH, Gulick RM, Dubler NN. Rethinking non-adherence; historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med. 1998;129:573-578.
48. Gifford AL, Shively MJ, Bormann JE, et al. Self-reported adherence to combination antiretroviral medication regimens in a community-based sample of HIV-infected adults [abstract 32338]. Presented at the 12th International AIDS Conference, Geneva, June-July 1998.
49. Klosinski LE, Brooks RN. Predictors of non-adherence to HIV combination therapies [abstract 32375]. Presented at the 12th International AIDS Conference, Geneva, June-July 1998.
50. Spire B, Duran S, Souville M, et al. (APROCO cohort study group). Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481-1496.
51. Besch L. Compliance in clinical trials. AIDS. 1995;9:1-10.
52. Hirschhorn L, Quinones J, Goldin S, et al. Highly active antiretroviral therapy in the "real world": experiences in an inner-city community health center [abstract 32334]. Presented at the 12th International AIDS Conference, Geneva, June-July 1998.
53. Bangsberg DR, Zolopa AR, Charlesbois E, et al. HIV-infected homeless and marginally housed patients adhere to and receive early virologic benefits from protease inhibitors [abstract 152]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1999.
54. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824-830.
55. Siegel K, Karus D, Schrimshaw EW. Racial differences in attitudes toward protease inhibitors among older HIV-infected men. AIDS Care. 2000;12:423-434.
56. Kemppainen JK, Levine RE, Mistal M, et al. HAART adherence in culturally diverse patients with HIV/AIDS study of male patients from a veteran's administration hospital in Northern California. AIDS Patient Care STDs. 2001;15:117-127.
57. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11:1665-1670.
58. Bogart LM, Catz SL, Kelly JA, et al. Factors influencing physician treatment decisions for patients with HIV disease. Med Decis Making. 2001;21:28-36.
59. Mostashari F, Riley E, Selwyn PA, et al. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:341-348.
60. Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence [abstract 98]. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January-February 1999.
61. Chesney MA, Ickovics J, Hecht FM, et al. Adherence: a necessity for successful HIV combination therapy. AIDS. 1999;13(Suppl):S1-S8.
62. Friedland GH. Adherence, compliance, and HAART. AIDS Clin Care. 1997;9:51-54.
63. Bertholon DR, Rossert H, Korsia S. The patient's perspective on life with antiretroviral treatment: results of an 887-person survey. AIDS Reader. 1999;9:462-469.
64. Katzenstein D. Strategies to improve medication compliance. J Assoc Nurses AIDS Care. 1997;8:18-24.
65. Brown MA, Inouye J, Powell-Cope GM, et al. Social support and adherence in HIV+ persons [abstract 32346]. Presented at the 12th International AIDS Conference. Geneva, June-July 1998.
66. Kunches L, Mazzullo JM, Miller-Mack E, et al. Educational and support needs of people living with HIV to improve adherence to HAART [abstract 32333]. Presented at the 12th International AIDS Conference, Geneva, June-July 1998.
67. McPherson-Baker S, Malow RM, Penedo F, et al. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care. 2000;12:399-404.
68. Akshita M, Ouchi Y, Toba K, et al. Compliance with prescriptions and adverse drug reactions in the elderly. Nippon Ronen Igakkai Zasshi. 1995;32:178-182.
69. Watson DC, Farley JJ, Lovelace S, et al. Efficacy and adherence to highly active antiretroviral therapy in HIV-1 infected children [abstract 230]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998.
70. Ward P, Grimshaw PJ. The development of effective media campaigns to encourage compliance with anti-HIV treatment [abstract 32394]. Presented at the 12th International AIDS Conference, Geneva, June-July 1998.
71. Nissen JC, Gajewski L, Grimone AJ, et al. Nationwide protease inhibitor adherence program [abstract 32327]. Presented at the 12th International AIDS Conference, Geneva, June-July 1998.
72. Byrd R, Fisher AE, Melbourne KM, et al. Support intervention to enhance medication adherence [abstract 32349]. Presented at the 12th International AIDS Conference, Geneva, June-July 1998.
73. Loor R, Amberg M, Moore P. Interventions to support patient adherence to HAART [abstract 1]. Presented at the 1999 National HIV Prevention Conference, Atlanta, August 1999.